Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR-T (Shenzhen Geno-Immune Medical Institute)
- Development stage
- Unknown
- Lead developer
- Shenzhen Geno-Immune Medical Institute
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-BCMA CAR-T (Shenzhen Geno-Immune Medical Institute) is an autologous or allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA; TNFRSF17), a protein highly expressed on the surface of malignant plasma cells in multiple myeloma and plasmacytoma. Developed by the Shenzhen Geno-Immune Medical Institute (GIMI), the CAR construct features a multi-domain intracellular signaling architecture comprising CD28, CD27, and CD3ζ to optimize T-cell activation, proliferation, and persistence. The therapy is currently being evaluated in Phase 1/2 clinical trials (e.g., NCT06429150, NCT03271632) as both a standalone treatment and as part of a multi-target CAR-T strategy, often combined with anti-GPRC5D CAR-T cells, to address high-risk disease and prevent antigen-escape-mediated relapse.
- Other names
- BCMA CAR-T (GIMI)anti-TNFRSF17 CAR-Tanti-TNFRSF-17 CAR-Tanti-TNFRSF 17 CAR-T
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR-T (Shenzhen Geno-Immune Medical Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR-T (Shenzhen Geno-Immune Medical Institute).